Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Exclusive: Novavax delays EU vaccine supply deal amid production problems - source

Stock MarketsMar 25, 2021 12:45PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration

By Francesco Guarascio and Carl O'Donnell

BRUSSELS (Reuters) - Novavax (NASDAQ:NVAX) is delaying signing a contract to supply its COVID-19 vaccine to the European Union, an EU official involved in the talks told Reuters, as the U.S. biotech company warned it was struggling to source some raw materials.

Prolonging the talks might further complicate the EU's vaccination plans as the bloc had planned to sign a deal early this year for at least 100 million doses of Novavax's vaccine, with an option for another 100 million.

The EU official, who asked not to named as the talks are confidential, said the company had postponed signing a deal for weeks, citing legal issues in meetings with the bloc's vaccine negotiators.

"They are slowing down the process of finishing the contract," the official, who attended the meetings, told Reuters.

Informally, a Novavax executive had said a slow pace in negotiations was warranted because the company was having production problems, the EU official said.

A Novavax spokeswoman said in an email that talks with the EU over a supply deal continue, but declined to say more about the discussions.

She said the company was working "through some pandemic-related raw materials supply shortages", without giving details.

The European Commission, which coordinates talks with vaccine makers, declined to comment.

Facing supply problems from other COVID-19 vaccine makers, notably AstraZeneca (NASDAQ:AZN), the EU's immunisation campaign is lagging far behind those in the United States and Britain, a situation that has become more critical as a third wave of infections sweeps the bloc.

Novavax is planning to produce key components of its two-dose vaccines for the EU in several of its factories, it said, including one in the Czech Republic, which makes antigens, the inactivated organisms that trigger an immune response.

The EU official said production capacity at the plant, the only one in the EU, was too small the meet the needs of the 27-nation bloc.

A spokesman for the plant declined to comment.

Novavax has eight manufacturing locations, including the Serum Institute of India, the world's biggest vaccine maker.

Serum warned earlier this month that a temporary U.S. ban on exports of critical raw materials could hurt its production of vaccines, including Novavax's.

Serum is also making AstraZeneca's COVID-19 vaccine and has suspended major exports of the shot.

It's not clear if Serum's issues are affecting Novavax's potential supplies to the EU.

Novavax executives said in an investor call earlier this month its vaccine production plants should all be fully functional by April.

CEO Stanley Erck told Reuters on March 1 the company expected to have tens of millions of doses stockpiled and ready to ship in the United States when it receives regulatory approval there, possibly in May.


Novavax concluded exploratory talks with the EU in mid-December, a step that has usually been followed by the signature of a contract within two or three months, according to EU deals with other COVID-19 vaccine makers.

At a meeting in mid-February, the Commission told EU ambassadors a deal with Novavax was likely to be finalised in a week, an official who attended that meeting said. A second EU official, involved in talks with the firm, also said in February that a deal was close.

But the same official told Reuters on Thursday that talks were ongoing and the company was now saying it aimed for a deal by June, although the official added the timeline was not clear.

Novavax says it is working towards submitting an application for regulatory approval in the EU in the second quarter.

Regulatory approval is a precondition for a vaccine to be rolled out in the bloc, but its absence has not prevented the EU from signing vaccine supply deals.

All EU supply contracts have so far been signed before regulatory approval, with the EU usually making upfront payments to companies and agreeing the full price for vaccines would only be paid after regulatory authorisation.

Novavax's vaccine has been assessed by the EU drugs regulator under a rolling review since early February.

Earlier in March, Novavax said its vaccine was highly effective in a late-stage trial in the United Kingdom.

Exclusive: Novavax delays EU vaccine supply deal amid production problems - source

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email